Effect of Rosuvastatin in Intracerebral Hemorrhage
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00364559|
Recruitment Status : Completed
First Posted : August 15, 2006
Last Update Posted : March 26, 2009
|Condition or disease||Intervention/treatment||Phase|
|Intracerebral Hemorrhage Stroke||Drug: Rosuvastatin||Phase 2|
The intracerebral hemorrhage (ICH) is a frequent problem of health, with high morbid-mortality. In addition it originates expensive expenses in health care systems.
ICH produces damage by mass effect, then by biochemical ways which are activated and they carry to secondary damage. Many studies have been conducted for explaining secondary injury, now we know there are ischemic changes related maybe with changes in cerebral flow and metabolism, in addition to activate inflammatory ways. Many drugs and measures has been ineffective for getting best outcome, without success.
Statins or inhibitors of HMG CoA reductase are drugs used in dyslipidemia, frequently for reduction in LDL. Experimental and clinical studies in stroke and ICH have shown improvement in outcome. The toxicity related to statin is myopathy and hepatopathy, both with low incidence without fatal cases. Rosuvastatin has been postulated be the most powerful with longest life and toxicity similar to another statins.
We have designed this study to demonstrate if the administration of rosuvastatin in the first 24 hours and by 14 days has improvement in outcome.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||75 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Effect of Rosuvastatin on Outcome by NIHSS After Intracerebral Hemorrhage|
|Study Start Date :||August 2006|
|Primary Completion Date :||December 2006|
|Study Completion Date :||December 2006|
A, Active B, Historical Register
20 mg 10 days daily
Other Name: Crestor
- NIHSSº [ Time Frame: basal and discharge ]
- Survivor [ Time Frame: within 1 month ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00364559
|Hospital Central "Dr. Ignacio Morones Prieto"|
|San Luis Potosi, Mexico, 78240|
|Study Director:||Ildefonso Rodríguez-Leyva, Neurology||Neurología, Hospital Central "Dr. ignacio Morones Prieto"|
|Principal Investigator:||Humberto Tapia-Perez, MD||Facultad de Medicina UASLP|